Equities

Imunon Inc

Imunon Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.03
  • Today's Change-0.04 / -3.74%
  • Shares traded439.67k
  • 1 Year change-5.50%
  • Beta2.1301
Data delayed at least 15 minutes, as of Sep 20 2024 20:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Imunon Inc have a median target of 10.00, with a high estimate of 14.00 and a low estimate of 8.00. The median estimate represents a 834.58% increase from the last price of 1.07.
High1,208.4%14.00
Med834.6%10.00
Low647.7%8.00

Earnings history & estimates in USD

On Aug 14, 2024, Imunon Inc reported 2nd quarter 2024 losses of -0.51 per share. This result exceeded the -0.540 consensus loss of the 3 analysts covering the company and exceeded last year's 2nd quarter results by 16.39%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate+0.18%
Imunon Inc reported annual 2023 losses of -2.16 per share on Mar 28, 2024.
Average growth rate+24.84%
More ▼

Revenue history & estimates in USD

Celsion Corporation did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Celsion Corporation did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 500.00k.
Average growth rate-25.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.